Results 71 to 80 of about 642,659 (199)

Early PCSK9 Inhibitor Therapy Following Percutaneous Coronary Intervention (PERFECT): A Pilot Randomized Controlled Trial

Cardiology Discovery
. Objective:. This study aimed to assess the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor treatment immediately after percutaneous coronary intervention (PCI) on the myocardial salvage index (MSI) in patients with anterior ...
Jiachun Xia, Zhengguang Xiao, Luyao Wu, Haiyang Yu, Yanan Pang, Shan Hu, Lei Hou, Hanjia Gao   +7 more
doaj   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression

Journal for ImmunoTherapy of Cancer
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a newly identified immunosuppressive regulator, but its mechanism of suppressing antitumor immunity remains ambiguous.
Rong Zhang, Xuan Wang, Yue Dai, Min Hu, Ming Qin, Changpeng Hu, Wenjing Lai, Huyue Zhou, Chengsha Yuan, Yafeng Liu, Mengmeng Yang, Menglin Luo, Guobing Li   +12 more
doaj   +1 more source

Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections

Chemistry – A European Journal, EarlyView.
Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley   +1 more source

PCSK9 Inhibitor Uptake Trends by Insurance Payers at Six Months Post FDA Approval [PDF]

, 2018
PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have shown superb efficacy in lowing LDL-C for patients who are not controlled by or are intolerant of first line medications such as high intensity statins and ezetimibe.
Vass, George Thomas
core  

PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro

Frontiers in Medicine
BackgroundThe co-occurrence of pulmonary hypertension (PH) in patients with pulmonary fibrosis (PF) is linked to a more unfavorable prognosis and increased mortality compared to PF cases without PH.
Jiancheng Lin, Jiancheng Lin, Jiancheng Lin, Zetao Pan, Zetao Pan, Zetao Pan, Jiayan Sun, Jiayan Sun, Jiayan Sun, Xiaowan Wang, Xiaowan Wang, Xiaowan Wang, Di Yin, Di Yin, Di Yin, Cunyang Huo, Cunyang Huo, Cunyang Huo, Qiang Guo, Qiang Guo, Qiang Guo, Qiang Guo   +21 more
doaj   +1 more source

Enlicitide (Lipfendra) – An Oral PCSK9 Inhibitor for LDL-Cholesterol Lowering

Enlicitide (Lipfendra – Merck), an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, has been approved by the FDA to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous ...

core   +1 more source

Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials.

PLoS ONE
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs used for the treatment of dyslipidemia. PCSK9 inhibitors have been shown to remarkably reduce cardiovascular events in patients at high risk, but data on ...
Lei Zhang, Yuan-Yuan Li, Xue-Hui Liu, Hong-Jun Liu, Qiang Xu   +4 more
doaj   +1 more source

Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Combining PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors with statins significantly lowers low‐density lipoprotein cholesterol and reduces cardiovascular events in patients with coronary heart disease versus statins alone ...
Linchan Yu, Boyang Xiang, Yuxin Ren, Yi Li, Jiaying Xie, Xiang Zhou   +5 more
doaj   +1 more source

TRIM31–LOX‐1 Axis: A Novel Therapeutic Frontier in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis, driven by a vicious cycle of lipid accumulation and chronic inflammation, underlies most cardiovascular diseases. Macrophages exacerbate this process by internalizing oxidized low‐density lipoprotein (oxLDL), forming foam cells, and releasing inflammatory mediators. A recent study published in Circulation identified the TRIM31–
Qian Zhang, Cheng Xue Qin
wiley   +1 more source